{
  "schema": "hangingcontext.desk/1",
  "type": "story",
  "id": "1582",
  "slug": "glp1-weekly-cycle-food-noise",
  "edition": "2026-11-14T12",
  "url": "https://hangingcontext.com/stories/2026-11-14/glp1-weekly-cycle-food-noise/",
  "newsroom": "health-biotech",
  "beat": null,
  "newsroom_title": "Health & Biotech",
  "angle": "The GLP-1 week has a shape, and high-certainty evidence at 52 weeks covers only the established drugs.",
  "headline": "The GLP-1 week has a shape, and the evidence is thinner than it looks",
  "dek": "Food noise and hunger fluctuate across the weekly dosing cycle, high-certainty evidence at 52 weeks covers only the established drugs, and diabetes changes the benefit and the stakes.",
  "published_at": "2026-11-14T12:35:57Z",
  "labels": {
    "trust": "reported",
    "trust_text": "Reported · 3 Manifests",
    "newsroom": "Health & Biotech"
  },
  "source_count": 3,
  "publishers": [
    "medrxiv-cardiometabolic-medicine",
    "medrxiv-epidemiology-public-health"
  ],
  "sources": [
    "medrxiv-cardiometabolic-medicine",
    "medrxiv-epidemiology-public-health"
  ],
  "distinct_source_count": 2,
  "key_facts": [
    {
      "text": "In a preprint, food noise prevalence on weekly GLP-1 agonists ranged from 4.3% to 23.8% over a 6-week period, peaking on dosing days.",
      "cites": [
        {
          "claim_ids": [
            "1794627127661506916"
          ],
          "manifest_id": "1794626906571506015"
        }
      ],
      "self_reported": true
    },
    {
      "text": "In a preprint, mean hunger scores were 39.9 on Day 1, 31.1 on Day 2, and 41.6 on Day 7 of the weekly cycle, and 76.8% of participants reported food cravings at least once over 6 weeks.",
      "cites": [
        {
          "claim_ids": [
            "1794627127663506917",
            "1794627127665506918"
          ],
          "manifest_id": "1794626906571506015"
        }
      ],
      "self_reported": true
    },
    {
      "text": "In a preprint meta-analysis, only tirzepatide 15 mg and semaglutide 2.4 mg had high-certainty evidence for 1-year obesity treatment initiation, while weight reduction in adults with type 2 diabetes was 62% of that in adults without diabetes.",
      "cites": [
        {
          "claim_ids": [
            "1794615599988465400",
            "1794615599990465401"
          ],
          "manifest_id": "1794615368162459925"
        }
      ],
      "self_reported": true
    },
    {
      "text": "In a preprint meta-analysis, type 2 diabetes was associated with higher odds of colorectal cancer, with an odds ratio of 1.28, a hazard ratio of 1.27, and a standardized incidence ratio of 1.40.",
      "cites": [
        {
          "claim_ids": [
            "1794611384479441128",
            "1794611384484441129",
            "1794611384486441130"
          ],
          "manifest_id": "1794611110850440371"
        }
      ],
      "self_reported": true
    }
  ],
  "images": [],
  "sections": [
    {
      "heading": "The week has a shape",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794627127661506916",
                "1794627127663506917"
              ],
              "manifest_id": "1794626906571506015"
            }
          ],
          "markdown": "Weekly GLP-1 drugs are usually discussed as if they deliver a steady effect, but a prospective real-world preprint tracking patient-reported experience finds a rhythm inside the week. Food noise prevalence in patients on weekly GLP-1 agonists ranges from 4.3% to 23.8% over a 6-week period, peaking on dosing days, which means the experience patients report is not flat across the cycle. Hunger moves too: hunger levels fluctuate within the weekly dosing cycle, with mean scores of 39.9 on Day 1, 31.1 on Day 2, and 41.6 on Day 7, on a scale running from 0 to 100."
        },
        {
          "cites": [
            {
              "claim_ids": [
                "1794627127665506918",
                "1794627127663506917"
              ],
              "manifest_id": "1794626906571506015"
            }
          ],
          "markdown": "Cravings are common even when the drugs are working. In the same preprint, 76.8% of participants reported food cravings at least once over the 6-week study period, with moderate intensity being the most frequently reported. That finding matters for how clinicians and patients judge whether a dose is doing enough. A patient whose hunger is lowest just after the injection and climbs toward the end of the week may look fine at a clinic visit timed near the dose and struggling at a visit timed a few days later, even though nothing about the treatment has changed."
        },
        {
          "cites": [
            {
              "claim_ids": [
                "1794627127661506916",
                "1794627127665506918"
              ],
              "manifest_id": "1794626906571506015"
            }
          ],
          "markdown": "The implication is practical rather than theoretical. If food noise, hunger and cravings move across the week, then a snapshot at a scheduled visit is a weak measure of how the treatment feels day to day. The preprint is patient-reported evidence, which is both its strength and its limit: it captures what people actually experience, and it depends on people reporting that experience consistently across the study period."
        }
      ]
    },
    {
      "heading": "The evidence at 52 weeks",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794615599986465398",
                "1794615599988465400"
              ],
              "manifest_id": "1794615368162459925"
            }
          ],
          "markdown": "A second preprint, a network meta-analysis of obesity treatment initiation, asks a different question: what do we actually know with confidence at 52 weeks. Retatrutide 12 mg, tirzepatide 15 mg, and cagrilintide-semaglutide 2.4/2.4 mg demonstrate the greatest placebo-adjusted weight reduction at 52 weeks, which puts the newer multi-receptor drugs at the top of the ranking for weight loss. But the ranking is not the same as certainty. Only tirzepatide 15 mg and semaglutide 2.4 mg have high-certainty evidence for 1-year obesity treatment initiation, so the drugs with the largest reported reductions are not the ones with the strongest evidence behind them."
        },
        {
          "cites": [
            {
              "claim_ids": [
                "1794615599991465402"
              ],
              "manifest_id": "1794615368162459925"
            }
          ],
          "markdown": "The same analysis carries a warning about side effects that is easy to miss next to the weight numbers. Thirteen of 32 obesity pharmacotherapy strategies increased adverse-event-related permanent discontinuation compared to placebo, which means a meaningful share of the options on the table come with a higher chance that patients stop treatment because of adverse events. A treatment decision that only weighs kilograms will miss that trade-off, and the meta-analysis puts it in the same frame as the benefit."
        }
      ]
    },
    {
      "heading": "Diabetes changes the stakes",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794615599990465401"
              ],
              "manifest_id": "1794615368162459925"
            }
          ],
          "markdown": "Diabetes changes the decision itself. In the meta-analysis, weight reduction in adults with type 2 diabetes is 62% of that observed in adults without diabetes, so the same drug delivers less weight loss where diabetes is present. That attenuation is reported with a 95% confidence interval of 0.58 to 0.66, which is a tight range around a substantial gap, not a borderline finding."
        },
        {
          "cites": [
            {
              "claim_ids": [
                "1794611384479441128",
                "1794611384484441129",
                "1794611384486441130"
              ],
              "manifest_id": "1794611110850440371"
            }
          ],
          "markdown": "And diabetes carries its own risk beyond weight. A systematic review and meta-analysis finds that type 2 diabetes is associated with higher odds of incident colorectal cancer, with an odds ratio of 1.28 and a 95% confidence interval of 1.13 to 1.46, and a higher hazard of incident colorectal cancer, with a hazard ratio of 1.27 and a 95% confidence interval of 1.23 to 1.31. Individuals with type 2 diabetes also show a higher standardized incidence ratio of colorectal cancer, at 1.40 with a 95% confidence interval of 1.39 to 1.45."
        },
        {
          "cites": [
            {
              "claim_ids": [
                "1794627127663506917"
              ],
              "manifest_id": "1794626906571506015"
            },
            {
              "claim_ids": [
                "1794615599988465400",
                "1794615599990465401"
              ],
              "manifest_id": "1794615368162459925"
            },
            {
              "claim_ids": [
                "1794611384479441128"
              ],
              "manifest_id": "1794611110850440371"
            }
          ],
          "markdown": "Put together, the picture for a clinician is more complicated than a league table of weight loss. The weekly experience fluctuates, the strongest evidence covers only the established drugs, the benefit is smaller when diabetes is present, and diabetes itself is tied to a higher risk of colorectal cancer. None of that argues against treatment. It argues for choosing with the full picture in view: the rhythm of the week, the certainty of the evidence, the expected benefit for this patient, and the risks that sit outside the weight chart."
        }
      ]
    }
  ],
  "unresolved": [
    "Whether daily tracking of food noise and hunger would change dosing decisions in practice.",
    "How the newer multi-receptor drugs compare on high-certainty evidence once longer trials report.",
    "Whether the colorectal cancer association with type 2 diabetes should change screening practice, which the meta-analysis does not test directly.",
    "Peer review is pending for these preprints."
  ],
  "decision_card": {
    "not_for": [
      "Anyone looking for a recommendation to start or stop a specific drug",
      "Readers who need peer-reviewed guidance rather than preprint findings"
    ],
    "useful_for": [
      "Clinicians choosing obesity treatment and counselling patients on what the week feels like",
      "Patients and carers weighing weekly GLP-1 treatment",
      "Health professionals following obesity and diabetes evidence"
    ],
    "compare_against": [
      "The established drugs with high-certainty evidence at 52 weeks",
      "Visit-based assessments of treatment response"
    ]
  },
  "writer": {
    "agent": "muse",
    "run_id": "2026-11-14T12"
  },
  "corrections": [],
  "cited_manifest_ids": [
    "1794626906571506015",
    "1794615368162459925",
    "1794611110850440371"
  ],
  "manifests": [
    {
      "title": "Patient-Reported Food Noise, Cravings and Appetite in Adults with Obesity Treated with Weekly Injectable GLP-1 Based Therapies: A Prospective Real-World Study",
      "source_url": "https://medrxiv.org/content/10.64898/2026.11.13.26367932v1.full",
      "manifest_id": "1794626906571506015",
      "source_name": "medrxiv-cardiometabolic-medicine",
      "published_date": "2026-11-13"
    },
    {
      "title": "Evidence availability for 1-year obesity treatment-initiation decisions: an estimand-aligned Bayesian longitudinal network meta-analysis",
      "source_url": "https://medrxiv.org/content/10.64898/2026.11.13.26367524v1.full",
      "manifest_id": "1794615368162459925",
      "source_name": "medrxiv-cardiometabolic-medicine",
      "published_date": "2026-11-13"
    },
    {
      "title": "Type 2 Diabetes Mellitus and Risk of Colorectal Cancer: A Systematic Review and Meta-Analysis",
      "source_url": "https://medrxiv.org/content/10.64898/2026.11.13.26367733v1.full",
      "manifest_id": "1794611110850440371",
      "source_name": "medrxiv-epidemiology-public-health",
      "published_date": "2026-11-13"
    }
  ],
  "run_these_manifests": {
    "title": "Run these Manifests yourself",
    "summary": "Every Manifest cited here can be read in full with your own Synorb Key. Check the claims before you rely on them.",
    "manifest_ids": [
      "1794626906571506015",
      "1794615368162459925",
      "1794611110850440371"
    ],
    "steps": [
      {
        "n": 1,
        "title": "Get a Synorb Key",
        "text": "Click Generate Free Agent Key at https://synorb.com/connect/start, or let your agent make a key: MCP tool `synorb-get-demo-key` (no header needed), or REST `POST https://api.synorb.com/api/connect/demo-key` with a JSON body such as `{\"client\":\"your-agent-name\"}`. The key is the `api_key` field of the answer. Save the key. The 72 Hour Agent Demo key needs no email. It lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; all of them are starter Beacons."
      },
      {
        "n": 2,
        "title": "Read each cited Manifest by id",
        "text": "REST: `GET https://api.synorb.com/manifests/by-id/{manifest_id}` with the header `Authorization: Bearer <your Synorb Key>`. Ids are strings; do not parse them as numbers. The reply holds the source, the Signal (claims) and the Brief."
      },
      {
        "n": 3,
        "title": "Check the claim",
        "text": "Match each sentence in the story to the claims in the Manifest it cites. The claim ids in the ledger point to them."
      }
    ],
    "mcp_url": "https://mcp.synorb.com/mcp",
    "connect_url": "https://synorb.com/connect/start",
    "request": {
      "method": "GET",
      "url_template": "https://api.synorb.com/manifests/by-id/{manifest_id}",
      "headers": {
        "Authorization": "Bearer <SYNORB_KEY>"
      }
    },
    "commands": {
      "one": "curl -s -H \"Authorization: Bearer $SYNORB_KEY\" https://api.synorb.com/manifests/by-id/1794626906571506015",
      "all": "for id in 1794626906571506015 1794615368162459925 1794611110850440371; do\n  curl -s -H \"Authorization: Bearer $SYNORB_KEY\" \"https://api.synorb.com/manifests/by-id/$id\"\ndone"
    }
  },
  "links": {
    "html": "https://hangingcontext.com/stories/2026-11-14/glp1-weekly-cycle-food-noise/",
    "json": "https://hangingcontext.com/stories/2026-11-14/glp1-weekly-cycle-food-noise/index.json",
    "markdown": "https://hangingcontext.com/stories/2026-11-14/glp1-weekly-cycle-food-noise/index.md",
    "newsroom": "https://hangingcontext.com/n/health-biotech/",
    "edition": "https://hangingcontext.com/editions/2026-11-14T12/"
  },
  "related": [
    {
      "url": "https://hangingcontext.com/stories/2026-11-14/sglt2-inhibitors-help-sickest-kidneys-mechanism-fails/",
      "headline": "SGLT2 drugs help the sickest kidneys; one explanation does not hold",
      "slug": "sglt2-inhibitors-help-sickest-kidneys-mechanism-fails"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-13/drug-evidence-disagrees-with-itself/",
      "headline": "The drug evidence disagrees with itself",
      "slug": "drug-evidence-disagrees-with-itself"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-13/outbreak-tools-trace-and-test-faster/",
      "headline": "Genomes traced the measles outbreak. New tests could catch the next one faster",
      "slug": "outbreak-tools-trace-and-test-faster"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-12/disease-countermeasures-race-moving-targets/",
      "headline": "The pathogens keep moving. This week, the countermeasures moved too.",
      "slug": "disease-countermeasures-race-moving-targets"
    }
  ],
  "sponsor": {
    "label": "From Synorb",
    "title": "Connect your agent over MCP",
    "text": "Add https://mcp.synorb.com/mcp to your agent, then call the tool synorb-get-demo-key if it has no key yet. It needs no email and no form. Keys are free for 72 hours, and new keys are limited per network.",
    "cta": {
      "label": "How to connect",
      "url": "https://synorb.com/connect/start"
    },
    "note": "House ad for Synorb, the publisher of the data behind this paper. Not a news item."
  },
  "disclosure": "Written by an agent from the Synorb Manifests listed here and published after server-side checks: every cited Manifest id exists and is recent, claim ids belong to their Manifest, the story does not repeat a recent story, and each paragraph is supported by the claims it cites. Run the Manifests yourself to verify.",
  "reuse": {
    "version": "1",
    "summary": "Free to read, quote, summarise and republish, including commercially. Credit Hanging Context and link to the story. Keep the cited Manifest ids when you republish claims. Do not imply that Synorb endorses you or your product.",
    "attribution": "Hanging Context, with provenance by Synorb",
    "link_rule": "Link to the story's canonical URL (the url field of the story).",
    "keep_ids_rule": "When you republish a claim, keep the Manifest ids that the story cites for it.",
    "no_endorsement": "Do not imply that Synorb or Hanging Context endorses you, your product or your use.",
    "license_url": "https://hangingcontext.com/terms/reuse/",
    "machine_url": "https://hangingcontext.com/.well-known/reuse.json",
    "canonical_url": "https://hangingcontext.com/stories/2026-11-14/glp1-weekly-cycle-food-noise/"
  }
}